METiS TechBio, XtalPi's First Ecosystem-Backed AI Drug Delivery Company, Successfully IPOs on HKEX, Marking Entry into Value Realization Phase for Industry-Leading Innovation Platform

METiS TechBio Co-Founder and CEO Dr. Lai Caida (right), Co-Founder Academician Chen Hongmin (left) celebrate the company's successful listing.

May 13, 2026, by XtalPi,2228.HK) Participate in early investment and ecological empowerment "The First Global AI Drug Delivery Stock"METiS TechBio (7666.HK) Officially Listed on HKEX, IPO Raises Over HKD 2.1 Billion, Public Offering Oversubscribed by More Than 6,900 Times, Breaking the 2026 Healthcare Record in Hong KongThis is another milestone in the AI pharmaceuticals field following METiS TechBio's debut on the Hong Kong Stock Exchange in 2024 as the "first AI pharmaceuticals stock."The successful launch of the first eco-empowerment project,Not onlyThis has brought considerable equity value returns to Metis TechBio, and strongly validated the investment empowerment model of its ecosystem platform enterprise.The AI innovation ecosystem built by METiS TechBio has fully entered the value realization phase.

XtalPi is the earliest investor and ecosystem enabler of METiS TechBio, deeply involved in its entrepreneurial conception, team building, and early technical empowerment. The founding teams of both companies come from MIT, similarly using AI as the technological core to build reusable underlying R&D platforms, and have successively gained recognition from top global pharmaceutical companies and leading investment institutions. From top-tier laboratories to entering the capital market, XtalPi has explored this path of technology industrialization for 10 years, while METiS TechBio took only 6 years. Today, METiS TechBio has built the world's largest library of ionizable lipids at the ten-million scale. Its AI-empowered new drug formulation, MTS-004, has advanced to Phase III clinical trials, making it the fastest-progressing AI-developed drug pipeline in China.

Thus, among the three AI pharmaceutical companies listed on the Hong Kong Stock Exchange, Jingtai Technology and its invested company METiS TechBio occupy two seats.This is not only a "pinnacle meeting" between two sibling enterprises, but also marks XtalPi's hard-tech investment empowerment model as a platform-based leading enterprise.Has Obtained Substantial Validation in the Open Market。

The Entrepreneurial Consensus Originated from MIT:

Breaking Through Cutting-Edge Concepts, Addressing Industry Pain Points

The intersection of Crystal and METiS TechBio's entrepreneurial journey traces back to an open day event for startup projects held on the MIT campus in the autumn of 2016.

In October 2016, Dr. Shu-Hao Wen (right), Chairman of the Board of METiS TechBio

Met METiS TechBio CEO Dr. Cai-Da Lai (left) at an MIT event

At that time, METiS TechBio, which had been founded for just over a year,Is committed to bringing cutting-edge AI Focused on solving the key challenge of drug crystal form prediction in new drug development.. InAt that event, Wen Shuhao, co-founder of XtalPi, met Caida Lai, who was still a Ph.D. student at MIT. LaiThe Myerson Lab, where Da is located, is a joint laboratory established by Novartis and MIT. Its research direction naturally spansBridging the Frontiers of Academia and Industrial Applications —— This aligns with METiS TechBio's dedication to bringingThe concept of transforming layered physics and AI algorithms into real industrial innovation power is highly in sync. Based on a similar scientific research background and pragmatic business acumen, Shuhao Wen immediately invited Caida Lai to join METiS TechBio as an early executive team member to drive the establishment of a closed-loop system for the company's AI prediction and wet-lab experimental validation.

At that time, AI-driven drug discovery was still an avant-garde and controversial direction. The drug development cycle is long, and most early drug discovery algorithms struggle to receive experimental closed-loop validation in the short term. As a result, the industry remains cautious, with only a few daring investors willing to take the bet.Few in number. However, METiS TechBio has chosen a different path: using the specific and verifiable technical aspect of crystal form prediction as an entry point,And participate in global blind testing competitions, thereby quickly verifying its quantum physics+AI The algorithm's leading advantages in precision, efficiency, and the complexity of systems it can handle have secured a ten-year strategic cooperation order with Pfizer.Obtained public endorsements from the world's top pharmaceutical companies. This milestone not only validates METiS TechBio's technical path but also provides direction for its next entrepreneurial journey.Lai Caida clearly sees that, with the rapid development of technology, market, and computing power, AI will become the prevailing trend in the pharmaceutical industry.

True collaborative entrepreneurship and ecological co-construction occurred a few years later. When Lai Caida decided to start a business again, the XtalPi team deeply participated in the project discussion. On Wen Shuhao's suggestion, he decided to apply AI capabilities to another high-barrier and highly promising aspect of drug research and development — formulation development and drug delivery — and further focus on the large-molecule drug delivery segment. Formulation andDrug delivery is closer to clinical applications, with stronger feasibility and easier realization of rapid validation and closed-loop platform capabilities. Subsequently, Chen Hongmin, scientific advisor of METiS TechBio, who is a member of both the National Academy of Sciences and the National Academy of Engineering in the United States, as well as AI algorithm expert Wang Wenshou, officially joined.Corresponding to XtalPi, the name "METiS TechBio" was born. The team was officially established in 2020, focusing on AI-driven nanodelivery systems, forming a deep industry chain synergy of "design + delivery" with XtalPi's drug discovery and design capabilities.Wen Shuhao Appointed as a Member of the METiS TechBio Board of Directors, Jiang Yide, Chief Strategy Officer of XtalPi, Serves as Industry Advisor.

Dr. Yi-De Jiang (right), Chief Strategy Officer of METiS TechBio, and Dr. Shu-Hao Wen, Chairman of the Board(Right Two)、METiS TechBio Co-Founder Academician Hongmin Chen (Right Three))、Dr. Lai Caida (second from the left)), Dr. Wang Wenshou (left) photographed in Kendall Square, Boston

At that time, XtalPi had completed its technological and commercial accumulation in the AI drug discovery field. Not only did it inject early-stage capital into METiS TechBio, but it also empowered METiS TechBio to quickly build its own R&D platform during its startup phase by leveraging the quantum physics algorithms and cloud-based supercomputing capabilities it had already established.

Thus, both XtalPi and METiS TechBio have chosen to enter the industry by focusing on key aspects of preclinical drug development—one moving upstream to build a one-stop AI + robotics drug discovery platform that spans multiple drug modalities such as small molecules, antibodies, peptides, siRNA, and molecular glues; the other delving deeper downstream,Self-developed the world's first AI nano-delivery platform,In just 6 years, it has built a pipeline of more than 10 projects, each growing into a benchmark AI-driven pharmaceutical company with rare R&D capabilities and having advanced multiple innovative drugs into clinical stages.

The First Global AI Drug Delivery Stock:

A Scarce Technology Platform Breaking Through the "Drug Delivery" Bottleneck

METiS TechBio's IPO has attracted significant market attention, primarily due to its direct confrontation with one of the most challenging engineering problems in the era of nucleic acid and gene therapy—how to precisely deliver drugs to the affected area.

Traditional lipid nanoparticles (LNPs) delivery has fundamental limitations: the vast majority of LNPs are passively captured by the liver, resulting in extremely low extrahepatic delivery efficiency, which severely restricts the clinical application of next-generation therapies such as mRNA and gene editing. METiS TechBio's self-developed...The World's First AI Nanodelivery Platform NanoForge, it is at this bottleneck that a system-level breakthrough has been achieved.It is expected to solve the "last mile" problem of new molecule drug development like a precision-guided rocket, bringing molecules and targets that traditional delivery methods cannot handle within range, and breaking the drug development curse where potential molecules fail in clinical trials due to delivery issues.

Based on the NanoForge platform, METiS TechBio has developed three major technical solutions: AiLNP (AI Nanoparticle Delivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform), and AiTEM (AI Small Molecule Formulation Design Platform), combining algorithms, intelligent agents, and high-throughput screening experiments.Covering multiple drug modalities, including small molecules and large molecules. A series of breakthroughs in platform capabilities,Advance the development of delivery systems from "trial-and-error experimentation" into the engineering era of "AI-driven design."Crossing from "in vitro"Effective"（in vitro）To "in vivo"Effective"（in vivo）The R&D Gap, allowing highly promising molecules to rapidly achieve clinical translation,And enhance the safety and efficacy of drugs. METiS TechBio has taken the lead in achieving precise targeted delivery to eight key organs and tissues: liver, lungs, heart, muscles, tumor tissues, immune system, central nervous system, and gastrointestinal tract. The efficiency of liver-targeted delivery exceeds the industry benchmark by 20 times.

In its commercialization strategy, METiS TechBio adopts a dual-driven business model of "platform cooperation + product cooperation" to form a recycling synergy ecosystem of "technology iteration - commercial application - real data feedback." METiS TechBio has established partnerships with over 30 pharmaceutical and biotech partners globally.Established 6 Years Ago, Already Has Over 10 Pipeline Products. Among them，MTS-004 is the first AI-enabled formulation new drug in China to complete Phase III clinical trials.It is also the only PBA (pseudobulbar affect) drug in China to have completed clinical trials, with the potential to fill a significant gap in clinical treatment. The entire process from project initiation to the completion of Phase III clinical trials took only 38 months.MTS-105 Expected to Become the World's First In Vivo mRNA-Encoded TCE Solid Tumor Therapy，For the treatment of liver cancer and other advanced solid tumors with liver metastases, it has entered investigator-initiated clinical trials.(IIT) PhaseAnd received orphan drug designation from the U.S. FDA.

METiS TechBio's platform capabilities have been doubly validated by the industry through clinical trials and licensing collaborations. The collaboration amount for its single-target platform can reach up to $109 million, with the total milestone payments for MTS-004 in the PBA indication approaching 1.85 billion RMB, providing the company with sustainable revenue and clear commercialization potential.

Notably, METiS TechBio, as the "world's first AI drug delivery stock," differs in technical focus from "the first AI pharmaceutical stock" and "the first AI + robotics stock," XtalPi, but their underlying logic is consistent:Both deeply integrate AI models, AI agents with high-throughput experimental systems, possess a core engine for continuously and autonomously generating high-quality data, and have built a cross-disciplinary, scalable, and reusable engineering platform that spans various drug modalities such as small and large molecules, nucleic acids, and more. This platform drives the dual growth of pipeline expansion and commercial collaboration through its capabilities.Crystal Therapeutics has defined a new paradigm for molecular discovery, while METiS TechBio has filled a critical gap in drug delivery. The successive IPOs of these two companies signify that AI has transcended its role as a mere "auxiliary tool" to become a core driving force behind pharmaceutical innovation breakthroughs and an underlying infrastructure spanning the entire chain, now achieving clinical translation and value creation at scale.

AI for Science Field

The First Ecological Platform Enterprise

Dr. Yi-De Jiang (fourth from the right), Chief Strategy Officer of XtalPi, attended the listing ceremony of METiS TechBio along with the founding team and investor representatives.

The essence of METiS TechBio is that it is an ecological platform enterprise. This attribute determines that its growth logic does not depend on the success or failure of a single pipeline or project, but ratherBy laying out a reusable underlying capability to build a diversified innovation ecosystem, systematically driving the dense emergence of innovative achievements, and reaping corresponding financial and commercial returns.METiS TechBio's DiverseEcological networks and industrial implementation capabilities have become the scarcest resources in the AI for Science era, fostering a unique investment and incubation model.

To date, XtalPi has invested in and incubated over 30 technology startups with unique technical advantages, covering new drugs, new materials, and underlying algorithms.and other core fields, its ecological layout has gone beyond traditional financial investment and evolved into an in-depthEmpowerment of the Ecological Platform.METiS TechBio, as the first successful IPO investment case, has confirmed the investment insight of XtalPi.The feasibility of this empowerment path marks that METiS TechBio has built a unique moat in the industrial implementation capability in the AI for Science field.

For a long time, the development of new drugs and new materials has been plagued by the underlying contradictions of high trial-and-error costs, long validation cycles, and the difficulty of scaling up experience migration. To break this industrial deadlock, XtalPi has沉淀ed quantum physics, AI, and large-scale robotic automation experimental capabilities into three core competitive advantages——A sustainably iterative AI + robotics foundational platform, large-scale engineering innovation capabilities, and an open innovation ecosystem with synergistic advantages.

With the叠加 of three capabilities, METiS TechBio is becoming the "global scientific infrastructure" in the AI for Science era. By continuously reusing algorithms and automated experimental clusters, the platform accumulates cross-disciplinary real data, enabling sustainable and scalable source innovation to tackle industrial challenges that are both highly difficult and highly rewarding.

Currently,This underlying platform has demonstrated high transferability across modalities and fields. In a wide range of areas such as small molecules, antibodies, peptides, nucleic acids, and molecular glues, XtalPi's system empowerment capabilities are rapidly translating into tangible results for its invested companies:Empower SigBiotech(AI + Organoid New Drug Discovery)、LaiMang Bio(Ultra-low Dose Next-generation Cell Therapy)、Moda Bio(Next-Generation Platform Drugs under Immunometabolic Mechanisms), Xili Tech(AI+RNA Targeting Rare Diseases and Autoimmune Disorders)Multiple innovative drugs from pipeline companies achieve clinical transformation; Empower METiS TechBio(AI + Organ-on-a-Chip), Deep Principle(AI New Material Discovery）, METiS TechBio（One-Click Antibody GenerationTechnical platform companies achieve milestone progress.These densely implemented cases demonstrate that METiS TechBio has established an efficient and replicable commercial closed loop, continuously creating value for the industry and investors.

Looking to the future, METiS TechBio will continue to adhere to long-termism, acting as a technology enabler and ecosystem builder. Relying on standardized and scalable AI and robotics platforms, it aims to transform cutting-edge algorithms into real innovation and productivity in the fields of new drug development and new materials. On the vast frontier of AI for Science, METiS TechBio is committed to allowing more scientific insights and "crazy yet correct" ideas originating from top laboratories to take root and sprout in the industrial soil with higher certainty, transforming them into forces that drive the industry forward and enhance human health and well-being.Continue to ring the victory bell of commercialization.

● CloseInMETiS TechBio ●

AI Nano-Delivery, Unlocking a Healthy Future. METiS TechBio is a biotechnology company innovating nanomaterials driven by artificial intelligence (AI), focusing on utilizing targeted drug delivery and drug discovery technologies to help living organisms combat diseases and aging, restoring health and vitality.

METiS TechBio, founded in 2020 by Dr. Hongmin Chen, a member of the US National Academy of Engineering, along with MIT scientists Dr. Caida Lai and Dr. Wenshou Wang, has received important qualifications such as the National Specialized and New "Little Giant" and National High-tech Enterprise. The company has independently developed NanoForge, the world's first artificial intelligence-driven nanodelivery platform, which boasts the largest lipid nanoparticle (LNP) library in the world, with tens of millions of LNPs. Based on NanoForge, METiS TechBio has created three core solutions: AiLNP (AI Nanodelivery System Design Platform), AiRNA (AI mRNA Sequence Design Platform), and AiTEM (AI Small Molecule Formulation Design Platform).

The company has achieved the capability to precisely target delivery to eight key organs or tissues, including the liver, lungs, muscles, and immune cells, making breakthrough progress in solving the challenges of multi-organ and multi-tissue targeted delivery. This provides druggable opportunities for cancer, metabolic system diseases, autoimmune diseases, neurodegenerative diseases, etc., and also offers possibilities for anti-aging at the organ level in living organisms.